= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Moran

MSACL 2018 EU Abstract

Topic: Glycomics

Podium Presentation in the Ether on Wednesday at 15:10 (Chair: TBA)

Characterisation of Prostate-Specific Antigen Isolated from Patients’ Urine

Alan Moran (Presenter)
Leiden University Medical Centre

Presenter Bio(s): Alan Moran, from Ireland, joined GlySign in 2017 under the supervision of Prof. Dr. Manfred Wuhrer, Guinevere Kammeijer (LUMC, NL), and Dr. Daniel Spencer (Ludger Ltd., UK). He will spend a significant proportion of his PhD at each institution where he will focus on the analysis of the glycosylation of prostate-specific antigen (PSA) in prostate cancer in order to improve patient stratification. For this purpose, Alan is exploring the usage of a variety of separation techniques (LC/CE) and the on-line coupling (ESI) to mass spectrometry (Q-TOF/FT-ICR), as well as the development and validation of a clinical assay. His scientific interests include the translation of proteomic and glycomic research to the clinics and industry.

Authors: A.B. Moran (1), G.S.M. Kammeijer (1), J. Nouta (1), T.M. de Reijke (2), E. Dominguez Vega (1), M. Wuhrer (1)
(1) Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, The Netherlands (2) Academic Medical Center, Department of Urology, University of Amsterdam, Amsterdam, The Netherlands


The glycoprotein prostate specific antigen (PSA) is a clinical biomarker of prostate cancer (PCa) but has a rather poor specificity and predictive value limiting its value for PCa diagnosis. It has been hypothesized that through examining its glycosylation, PSA could be used as a more specific biomarker of PCa. This study presents a novel approach to analyse the glycosylation variants as well as other proteoforms of PSA from patients’ urine using capillary electrophoresis coupled to a mass spectrometer with a sheathless interface (CE-ESI-MS). Analysis of intact PSA revealed a wide variety of glycoforms and proteoforms and results obtained from intact and glycopeptide analysis were compared.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: